These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. Kurihara N; Kubota T; Hoshiya Y; Otani Y; Ando N; Kumai K; Kitajima M J Surg Oncol; 1996 Jun; 62(2):135-8. PubMed ID: 8649040 [TBL] [Abstract][Full Text] [Related]
15. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. de Jonge MJ; Slingerland M; Loos WJ; Wiemer EA; Burger H; Mathijssen RH; Kroep JR; den Hollander MA; van der Biessen D; Lam MH; Verweij J; Gelderblom H Eur J Cancer; 2010 Nov; 46(16):3016-21. PubMed ID: 20801016 [TBL] [Abstract][Full Text] [Related]
17. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected. Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725 [TBL] [Abstract][Full Text] [Related]
18. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment. Toral-Martiñón R; Shkurovich-Bialik P; Collado-Corona MA; Mora-Magaña I; Goldgrub-Listopad S; Shkurovich-Zaslavsky M Arch Med Res; 2003; 34(3):205-8. PubMed ID: 14567400 [TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185 [TBL] [Abstract][Full Text] [Related]
20. Profound hearing loss from intravertebral artery cisplatin. Wetmore SJ; Koike KJ; Bloomfield SM Otolaryngol Head Neck Surg; 1997 Feb; 116(2):234-7. PubMed ID: 9051071 [No Abstract] [Full Text] [Related] [Next] [New Search]